Clinical Trial Update: A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with nab-paclitaxel and famitinib as first-line therapy for unresectable locally advanced or metastatic tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Fudan University | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: UNKNOWN